Clinical Trial Update: Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC

View source ↗

Summary

Real-world study examining how local therapy decisions change during first-line lorlatinib treatment for unresectable ALK-positive non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• lorlatinib (lorlatinib)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Lung Cancer, Non-Small Cell | Status: NOT_YET_RECRUITING